Cargando…

RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study

BACKGROUND: To evaluate the objective response rate (ORR) at 2 months of treatment with regorafenib according to RECIST 1.1, Choi, and modified Choi (mChoi) criteria in patients with metastatic colorectal cancer (mCRC). METHODS: Baseline and 2-month contrast-enhanced computed-tomography (CECT) scans...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lucidarme, Olivier, Wagner, Mathilde, Gillard, Paul, Kim, Stefano, Bachet, Jean-Baptiste, Rousseau, Benoit, Mazard, Thibault, Louvet, Christophe, Chibaudel, Benoist, Cohen, Romain, Garcia-Larnicol, Marie-Line, Gobert, Aurelien, Henriques, Julie, André, Thierry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902493/ https://www.ncbi.nlm.nih.gov/pubmed/31818317 http://dx.doi.org/10.1186/s40644-019-0271-z

Ejemplares similares

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
por: Cohen, Romain, et al.
Publicado: (2020)

Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT
por: Zwirtz, Kevin, et al.
Publicado: (2022)

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial
por: Bachet, Jean-Baptiste, et al.
Publicado: (2015)

Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
por: Luo, Yanji, et al.
Publicado: (2017)

Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
por: Solis-Hernandez, Mª Pilar, et al.
Publicado: (2019)

Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial
por: Hamidou, Zeinab, et al.
Publicado: (2016)

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
por: Goldmacher, Gregory V., et al.
Publicado: (2020)

RECIST criteria: our experience in daily practice
por: De Luca, S, et al.
Publicado: (2015)

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment
por: Pastor, Brice, et al.
Publicado: (2021)

Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study
por: Diouf, Momar, et al.
Publicado: (2014)

Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021)

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)

RECIST rules
por: Sohaib, Aslam
Publicado: (2012)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
por: Anota, Amélie, et al.
Publicado: (2013)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?
por: Ades, Felipe, et al.
Publicado: (2015)

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
por: Min, Seon Jeong, et al.
Publicado: (2016)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial
por: Charton, Emilie, et al.
Publicado: (2019)

Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis
por: Kim, Hong Deok, et al.
Publicado: (2019)

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer
por: Chibaudel, Benoist, et al.
Publicado: (2016)

Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma
por: WENG, ZHIHONG, et al.
Publicado: (2013)

A Conversation with Insung Choi
por: Bourzac, Katherine
Publicado: (2016)

The Operational Choi–Jamiołkowski Isomorphism
por: Adlam, Emily
Publicado: (2020)

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
por: van Persijn van Meerten, Els L., et al.
Publicado: (2009)

The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
por: Lee, Jae Seung, et al.
Publicado: (2020)

Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors
por: Bachet, Jean-Baptiste, et al.
Publicado: (2010)

Is There a Limitation of RECIST Criteria in Prediction of Pathological Response, in Head and Neck Cancers, to Postinduction Chemotherapy?
por: Patil, V., et al.
Publicado: (2013)

PAHs: Choi et al. Respond
por: Choi, Hyunok, et al.
Publicado: (2009)

iRECIST: how to do it
por: Persigehl, Thorsten, et al.
Publicado: (2020)

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022)

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
por: van der Veldt, A A M, et al.
Publicado: (2010)

Immune RECIST Criteria and Symptomatic Pseudoprogression in Non-small Cell Lung Cancer Patients Treated with Immunotherapy
por: Vrankar, Martina, et al.
Publicado: (2018)

Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
por: Delgado-Ureña, Mayte, et al.
Publicado: (2018)

Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis
por: Kim, Jung Han, et al.
Publicado: (2015)

RECIST Applied to Realistic Tumor Models
por: Levine, Zachary H., et al.
Publicado: (2011)

Imaging tumour response: beyond RECIST
por: Koh, Dow-Mu
Publicado: (2014)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
por: Gil-Delgado, Maria Angeles, et al.
Publicado: (2018)

The Role of Dual-Energy CT for the Assessment of Liver Metastasis Response to Treatment: Above the RECIST 1.1 Criteria
por: Reginelli, Alfonso, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_un0ehkroltm9m28pcvmn5846oi